Lipidomics in drug discovery

Drug Discovery Today

Volumn 19, Issue 2, 2014, Pages 164-170

  Vihervaara, Terhi ^a   Suoniemi, Matti ^a   Laaksonen, Reijo ^a  

^a Zora Biosciences Oy   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; BIOLOGICAL MARKER; GLYCEROLIPID; GLYCEROPHOSPHOLIPID; GLYCOSPHINGOLIPID; ICOSANOID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SPHINGOLIPID; XIMELAGATRAN; LIPID;

ALZHEIMER DISEASE; APOPTOSIS; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL SURVIVAL; CHEMICAL STRUCTURE; DIABETES MELLITUS; DRUG DEVELOPMENT; DYNAMICS; ENERGY METABOLISM; GENE EXPRESSION; GENETIC ASSOCIATION; GOOD LABORATORY PRACTICE; HUMAN; HUNTINGTON CHOREA; HYPERLIPIDEMIA; LIPID DIET; LIPID METABOLISM; LIPIDOMICS; LIPOGENESIS; LIQUID CHROMATOGRAPHY; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NIEMANN PICK DISEASE; NONHUMAN; PARKINSON DISEASE; REVIEW; SCHIZOPHRENIA; SMOKING; SPINAL CORD INJURY; ANIMAL; CHEMISTRY; DRUG DESIGN; MEDICAL RESEARCH; METABOLISM; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; DRUG DESIGN; DRUG DISCOVERY; HUMANS; LIPID METABOLISM; LIPIDS; SIGNAL TRANSDUCTION;

EID: 84895918227     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.09.008     Document Type: Review

References (37)

1. C.S. Ejsing et al. Global analysis of the yeast lipidome by quantitative shotgun mass spectrometry Proc. Natl. Acad. Sci. U. S. A. 106 2009 2136 2141
2. A. Hiukka et al. ApoCIII-enriched LDL in type 2 diabetes displays sphingomyelinase, and increased binding to biglycan Diabetes 58 2009 2018 2026
3. D. Lindén et al. Liver-directed overexpression of mitochondrial glycerol-3-phosphate acyltransferase results in hepatic steatosis, increased triacylglycerol secretion and reduced fatty acid oxidation FASEB J. 20 2006 434 443
4. A.H. Futerman, and Y.A. Hannun The complex life of simple sphingolipids EMBO Rep. 5 2004 777 782
5. W. Zheng et al. Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy Biochim. Biophys. Acta 1758 2006 1864 1884
6. A.E. Alewijnse, and S.L.M. Peters Sphingolipid signalling in the cardiovascular system: good, bad or both? Eur. J. Pharmacol. 585 2008 292 302
7. Y.A. Hannun, and L.M. Obeid Principles of bioactive lipid signalling: lessons from sphingolipids Nat. Rev. Mol. Cell Biol. 9 2008 139 150
8. D. Hartmann et al. Long chain ceramides and very long chain ceramides have opposite effects on human breast and colon cancer cell growth Int. J. Biochem. Cell B 44 2012 620 628
9. K. Ekroos et al. Lipidomics Technologies and Applications 2012 Wiley-VCH
10. L.A. Heiskanen et al. Long-term performance and stability of molecular shotgun lipidomic analysis of human plasma samples Anal. Chem. 2013 10.1021/ac401857a
11. H. Ogiso et al. Development of a reverse-phase liquid chromatography electrospray ionization mass spectrometry method for lipidomics, improving detection of phosphatidic acid and phosphatidylserine Anal. Biochem. 375 2008 124 131
12. A. Kuksis et al. Plasma lipid profiling by liquid chromatography with chloride-attachment mass spectrometry Lipids 26 1991 240 246
13. G. Hopfgartner et al. Triple quadrupole linear ion trap mass spectrometer for the analysis of small molecules and macromolecules J. Mass Spectrom. 39 2004 845 855
14. R.L. Shaner et al. Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers J. Lipid Res. 50 2009 1692 1707
15. R. Herzog et al. LipidXplorer: a software for consensual cross-platform lipidomics PLoS ONE 7 2012 e29851
16. P. Haimi et al. Software tools for analysis of mass spectrometric lipidome data Anal. Chem. 78 2006 8324 8331
17. H.R. Jung et al. High throughput quantitative molecular lipidomics Biochim. Biophys. Acta 1811 2011 925 934
18. S. Boué et al. Modulation of atherogenic lipidome by cigarette smoke in apolipoprotein E-deficient mice Atherosclerosis 225 2012 328 334
19. C. Stegemann et al. Comparative lipidomics profiling of human atherosclerotic plaques Circ. Cardiovasc. Genet. 4 2011 232 242
20. W. Yin et al. Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia J. Lipid Res. 53 2012 51 65
21. K. Suhre et al. Human metabolic individuality in biomedical and pharmaceutical research Nature 477 2011 54 60
22. M. Furuhashi et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2 Nature 447 2007 959 965
23. M. Morita et al. The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza Cell 153 2013 112 125
24. H.K. Min et al. Shotgun lipidomics for candidate biomarkers of urinary phospholipids in prostate cancer Anal. Bioanal. Chem. 399 2011 823 830
25. P. Bougnoux et al. The lipidome as a composite biomarker of the modifiable part of the risk of breast cancer Prostaglandins Leukot. Essent. Fatty Acids 79 2008 93 96
26. A. Llorente et al. Molecular lipidomics of exosomes released by PC-3 prostate cancer cells Biochim. Biophys. Acta 1831 2013 1302 1309
27. X. Zhou et al. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics PLoS ONE 7 2012 e48889
28. M.R. Wenk The emerging field of lipidomics Nat. Rev. Drug Discov. 4 2005 594 610
29. N.G. Carlson, and J.W. Rose Antioxidants in multiple sclerosis: do they have a role in therapy? CNS Drugs 20 2006 433 441
30. J. McEvoy et al. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics PLoS ONE 8 2013 e68717
31. E.D. Hall, and J.E. Springer Neuroprotection and acute spinal cord injury: a reappraisal NeuroRx 1 2004 80 100
32. R.M. Adibhatla, and J.F. Hatcher Role of lipids in brain injury and diseases Future Lipidol. 2 2007 403 422
33. O. Quehenberger et al. Lipidomics reveals a remarkable diversity of lipids in human plasma J. Lipid Res. 51 2010 3299 3305
34. O. Sergent et al. Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes Toxicol. In vitro 23 2009 1305 1310
35. M.T. Jänis et al. Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency Atherosclerosis 228 2013 380 385
36. S. Gupta et al. Integration of lipidomics and transcriptomics data towards a systems biology model of sphingolipid metabolism BMC Syst. Biol. 5 2011 26
37. L. Kuerschner et al. Polyene-lipids: a new tool to image lipids Nat. Meth. 2 2005 39 45